[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:klk3-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"KLK3 Gene",37,33,[8,16,22,29,36,42,48,55,61,67,73,79,85,91,98,104,110,116,122,128,133,139,145,151,157,163,168,174,181,187,193,199,205,211,218,224,231],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06111781","The SUGAR Study; SBRT and Relugolix) for Prostate Cancer",[12],"Phase 2","RECRUITING","2026-08-26T02:15:52.238965Z","2026-07-05T05:32:16.747956Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05915442","Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer",[12],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:29.710200Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07319871","A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer",[26],"Phase 1","2026-08-26T02:18:31.944757Z","2026-05-05T02:43:29.524087Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT03424850","Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy",[33],"Phase 1\u002FPhase 2","2026-08-26T02:17:57.997171Z","2026-05-05T02:43:29.365294Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05818683","A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer",[26],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:29.352319Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06067841","A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer",[26],"2026-08-26T02:16:00.194860Z","2026-05-05T02:43:29.282638Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT05512754","Impact of Anti-inflammatory Medications in Patients With Elevated Serum Prostate-specific Antigen",[52],"Phase 4","2026-08-26T02:15:51.395565Z","2026-05-05T02:43:29.227239Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06200259","Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement",[],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:29.225577Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05125016","A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer",[33],"2026-08-26T02:18:17.950264Z","2026-05-05T02:43:29.014696Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07313241","Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)",[12],"2026-08-26T02:15:03.757872Z","2026-05-05T02:43:28.850457Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05610852","Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound",[],"2026-08-26T02:17:32.059863Z","2026-05-05T02:43:28.736397Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04288427","5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy",[],"2026-08-26T02:19:29.922117Z","2026-05-05T02:43:28.221022Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT03767595","ProACT Post-Approval Study",[],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:28.187354Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT03769766","Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance",[95],"Phase 3","2026-08-26T02:17:41.695983Z","2026-05-05T02:43:27.975645Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT06111313","The University of Miami Adapt (UAdapt) Trial",[12],"2026-08-26T02:18:21.216897Z","2026-05-05T02:43:27.857905Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT07244341","A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)",[26],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.425917Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06150417","MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)",[12],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:27.060381Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05629494","Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test",[52],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:26.691725Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT05036226","COAST Therapy in Advanced Solid Tumors and Prostate Cancer",[33],"2026-08-26T02:16:33.772093Z","2026-05-05T02:35:31.916710Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":20,"content_modified":132},"NCT06554717","Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV",[12],"2026-07-05T05:32:16.760081Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT07567027","Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)",[],"2026-08-26T02:18:00.873391Z","2026-05-13T02:55:06.731113Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06496256","Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial",[],"2026-08-26T02:19:12.219640Z","2026-05-05T02:43:26.963122Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07231627","AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions",[],"2026-08-26T02:17:02.694423Z","2026-05-29T15:36:40.183465Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT05948657","Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr",[],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:28.887267Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07285057","Diagnostic Utility of rhPSMA-7.3 (18F) PET\u002FCT in Men With Prostate Cancer on Active Surveillance",[12],"2026-08-26T02:17:28.381459Z","2026-05-05T02:43:27.742240Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":34,"content_modified":167},"NCT06617481","PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence",[12],"2026-05-05T02:43:27.730804Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT07084779","Investigation of Impact of AI on Prostate Cancer Workflow",[],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:27.090210Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":179,"content_modified":180},"NCT06813898","An Investigational Scan (rhPSMA-7.3 PET\u002FCT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial",[178],"Early Phase 1","2026-08-26T02:16:38.897933Z","2026-05-05T02:43:26.925501Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT07052214","PSMA PET Combined With MRI for the Detection of PCa",[95],"2026-08-26T02:19:00.742020Z","2026-07-24T01:27:14.902259Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT07543757","Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix",[],"2026-08-26T02:15:18.897219Z","2026-05-13T02:55:06.721083Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT07492927","Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer",[],"2026-08-26T02:18:19.586423Z","2026-05-13T02:55:06.709965Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT07077239","Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity",[],"2026-08-26T02:19:23.493898Z","2026-05-13T02:55:06.651249Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT06594887","Rectal Spacers Use in Prostate Cancer Radiation Therapy",[],"2026-08-26T02:16:36.513735Z","2026-05-05T02:43:28.131537Z",{"nct_id":212,"title":213,"phases":214,"status":215,"updated_at":216,"content_modified":217},"NCT06660862","Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.",[52],"NOT_YET_RECRUITING","2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.880266Z",{"nct_id":219,"title":220,"phases":221,"status":215,"updated_at":222,"content_modified":223},"NCT07328542","Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men",[52],"2026-08-26T02:18:24.494016Z","2026-05-05T02:43:28.530265Z",{"nct_id":225,"title":226,"phases":227,"status":228,"updated_at":229,"content_modified":230},"NCT04989946","Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer",[33],"ACTIVE_NOT_RECRUITING","2026-08-03T02:41:09.847474Z","2026-05-05T02:43:28.193052Z",{"nct_id":232,"title":233,"phases":234,"status":235,"updated_at":236,"content_modified":237},"NCT05799248","Role of rhPSMA-7.3 PET\u002FCT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management",[95],"UNKNOWN","2026-08-03T03:08:36.511561Z","2026-05-05T02:43:27.446876Z"]